Alta Fundamental Advisers LLC Has $4.97 Million Holdings in Indivior PLC (NASDAQ:INDV)

Alta Fundamental Advisers LLC boosted its stake in Indivior PLC (NASDAQ:INDV - Free Report) by 23.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 400,000 shares of the company's stock after buying an additional 75,000 shares during the period. Indivior accounts for approximately 1.5% of Alta Fundamental Advisers LLC's investment portfolio, making the stock its 17th largest holding. Alta Fundamental Advisers LLC owned 0.29% of Indivior worth $4,972,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ardsley Advisory Partners LP lifted its holdings in Indivior by 11.0% in the 4th quarter. Ardsley Advisory Partners LP now owns 1,200,000 shares of the company's stock valued at $14,916,000 after acquiring an additional 119,050 shares during the last quarter. Foursixthree Capital LP bought a new stake in Indivior during the fourth quarter valued at about $4,639,000. Jane Street Group LLC boosted its holdings in Indivior by 101.9% in the 4th quarter. Jane Street Group LLC now owns 36,881 shares of the company's stock valued at $473,000 after purchasing an additional 18,611 shares during the period. PDT Partners LLC raised its stake in shares of Indivior by 4.7% in the fourth quarter. PDT Partners LLC now owns 57,520 shares of the company's stock valued at $715,000 after purchasing an additional 2,596 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Indivior during the 4th quarter worth approximately $1,686,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Trading Down 4.0 %

Shares of NASDAQ:INDV traded down $0.46 during mid-day trading on Thursday, reaching $11.02. The stock had a trading volume of 450,193 shares, compared to its average volume of 989,015. The firm has a market cap of $1.52 billion, a PE ratio of -31.49 and a beta of 0.98. The firm has a 50 day simple moving average of $9.92 and a two-hundred day simple moving average of $10.50. Indivior PLC has a twelve month low of $7.33 and a twelve month high of $18.59.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.19. The company had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. On average, equities analysts anticipate that Indivior PLC will post 1.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on INDV shares. Piper Sandler reduced their target price on Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a report on Thursday, March 6th. Rodman & Renshaw started coverage on shares of Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 target price on the stock. Finally, RODMAN&RENSHAW raised shares of Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.